Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 405.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,361,013 shares of the company's stock after buying an additional 4,301,212 shares during the period. Dimensional Fund Advisors LP owned 0.64% of Dr. Reddy's Laboratories worth $84,643,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RDY. Robeco Institutional Asset Management B.V. raised its position in Dr. Reddy's Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after purchasing an additional 9,373,412 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Dr. Reddy's Laboratories by 382.9% in the fourth quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock valued at $148,717,000 after buying an additional 7,467,979 shares during the last quarter. Aikya Investment Management Ltd boosted its stake in shares of Dr. Reddy's Laboratories by 416.1% during the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after buying an additional 4,523,303 shares during the period. Vanguard Group Inc. grew its holdings in shares of Dr. Reddy's Laboratories by 397.2% during the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after buying an additional 3,911,404 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Dr. Reddy's Laboratories by 462.1% in the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock valued at $44,444,000 after acquiring an additional 2,313,987 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Performance

Dr. Reddy's Laboratories stock traded up $0.17 during mid-day trading on Friday, reaching $14.00. 1,236,700 shares of the company were exchanged, compared to its average volume of 1,475,847. The firm's 50-day simple moving average is $13.23 and its two-hundred day simple moving average is $14.16. Dr. Reddy's Laboratories Limited has a twelve month low of $12.26 and a twelve month high of $16.89. The firm has a market cap of $11.69 billion, a PE ratio of 22.29 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Equities analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.